TOP TEN perturbations for 392_g_at (Homo sapiens)
Organism: Homo sapiens
Gene: 392_g_at
Selected probe(set): 201979_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 392_g_at (201979_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 16 (LN-215) / normal astrocyte sample
Relative Expression (log2-ratio):3.7464762Number of Samples:2 / 3
Experimental | glioma study 16 (LN-215) |
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):3.656907Number of Samples:2 / 3
Experimental | glioma study 16 (LN-319) |
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):3.250556Number of Samples:2 / 3
Experimental | glioma study 16 (LN-18) |
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):3.1128922Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):-2.7147493Number of Samples:43 / 2
Experimental | lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.7057152Number of Samples:2 / 22
Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted). |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):2.601039Number of Samples:2 / 3
Experimental | glioma study 16 (BS-149) |
Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
S. pneumoniae study 3 / S. pneumoniae study 4
Relative Expression (log2-ratio):2.527628Number of Samples:3 / 3
Experimental | S. pneumoniae study 3 |
Detroit 562 pharyngeal epithelial cells, infected with Streptococcus pneumoniae isogenic nonencapsulated derivative G54delta-cps. Bacteria were allowed to adhere to the epithelial cells for 2 hours. | |
Control | S. pneumoniae study 4 |
Detroit 562 pharyngeal epithelial cells, infected with Streptococcus pneumoniae G54WT. Bacteria were allowed to adhere to the epithelial cells for 2 hours. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.4444532Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
precursor-B-ALL study 7 (PDX; short-term; <10wk) / precursor-B-ALL study 7 (early relapse; <24m)
Relative Expression (log2-ratio):2.4093924Number of Samples:5 / 22
Experimental | precursor-B-ALL study 7 (PDX; short-term; <10wk) |
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis). | |
Control | precursor-B-ALL study 7 (early relapse; <24m) |
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse within 24 months after diagnosis (early relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457. |